Endo International has revealed that its Par Sterile Products division is now shipping posaconazole injection (18 mg/mL) in the United States. This marks the first generic version of Merck’s Noxafil, following the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application. Posaconazole injection is prescribed for the prevention […]
Strides Pharma Science Limited will acquire the manufacturing facility of Endo International in Chestnut Ridge, New York along with a portfolio of abbreviated new drug applications (ANDAs) for nearly $24 million. The Indian pharma company said that the deal will help it further strengthen its footprint in the US, courtesy of the multi dosage facility […]
Endo International has agreed to acquire BioSpecifics Technologies, a New York-based commercial-stage biopharma company, for $88.5 per share, or an estimated enterprise value of around $658 million. The Irish pharma company and BioSpecifics Technologies have been in a strategic partnership since 2004. BioSpecifics Technologies had developing a form of injectable collagenase clostridium histolyticum (CCH), which […]